Clinical trial
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
NCT00390091 · La Jolla Pharmaceutical Company, Industry · Withdrawn
Key facts
| NCT number | NCT00390091 |
|---|---|
| Title | Study of LJP 394 (Abetimus Sodium) in Lupus Patients |
| Official title | A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE) |
| Lead sponsor | La Jolla Pharmaceutical Company, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | abetimus sodium (LJP 394) |
| Enrollment | 0 |
| Start date | Sep 1, 2006 |
| First posted | Oct 19, 2006 |
| Last update posted | Sep 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: